作者
Antonino Tuttolomondo, Domenico Di Raimondo, Rosaria Pecoraro, Valentina Arnao, Antonio Pinto, Giuseppe Licata
发表日期
2012/9/1
来源
Current pharmaceutical design
卷号
18
期号
28
页码范围
4289-4310
出版商
Bentham Science Publishers
简介
Determining the cause of stroke does influence choices for management. categorization of subtypes of ischemic stroke has had considerable study, but definitions are hard to formulate and their application for diagnosis in an individual patient is often problematic. Cerebral ischemia initiates a complex cascade of events at genomic, molecular, and cellular levels, and inflammation is important in this cascade. In 1993 for For the Trial of Org 10172 in Acute Stroke Treatment (TOAST), Adams et al] conducted a placebo-controlled, randomized, blinded study of the low-molecular-weight heparinoid given to patients within 24 hours after stroke and developed a system for diagnosis of subtype of ischemic stroke that uses components of existing diagnostic schemes. The type of acute ischemic stroke was classified according to the TOAST classification: 1) Large Artery AtheroSclerosis (LAAS); 2) CardioEmbolic Infarct (CEI); 3 …
引用总数
201220132014201520162017201820192020202120222023202432831262515410231112125
学术搜索中的文章
A Tuttolomondo, D Di Raimondo, R Pecoraro, V Arnao… - Current pharmaceutical design, 2012